Latest
Sources
Trade Ideas
Speakers
Sign in
Go
The FDA Approves Merck's Keytruda And Keytruda Qlex Plus Paclitaxel, With Or Without Bevacizumab, For PD-L1+ Platinum-resistant Ovarian Carcinoma
Original source ↗
| February 11, 2026 at 07:51 UTC |
Finnhub - MRK
No analysis available.
Trade Ideas
Ticker
Direction
Speaker
Thesis
Time
MRK
NONE
Finnhub News
—
—